Glenmark obtains DCGI nod for clinical study of its GRC 54276 molecule

By Akshay Kedari  | Date: 2022-04-12

Glenmark obtains DCGI nod for clinical study of its GRC 54276 molecule

Glenmark Pharmaceuticals Limited has reportedly received approval from the DCGI (Drug Controller General of India) to perform phase 1 clinical trials of its novel molecule for advanced solid tumor patients.

Glenmark Specialty SA obtained the DCGI nod for GRC 54276, the company’s novel small molecule which is an HPK1 (hematopoietic progenitor kinase 1) inhibitor.

For those unaware, GRC 54276 is one of the several novel molecules from the company’s Innovative Medicines Group which specializes in the development of advanced molecular entities for crucial unsatisfied medical needs.

Speaking about the molecule, Glenmark stated that GRC 54276 has showcased the ability to eliminate tumour cells in preclinical studies through combination with checkpoint inhibitors as well as a single agent, further marking it as a key target in immuno-oncology.

The study will assess the tolerability and safety of GRC 54276 in combination with checkpoint inhibitors and as a monotherapy in patients with Hodgkin's lymphoma and advanced solid tumours.

Glenmark cited that it will commence Phase 1 clinical trial in India by June this year and intends to file an Investigational New Drug (IND) application in the United States as well as a clinical trial application in Europe to initiate a global clinical study program.

Glenn Saldanha, the Chairman & Managing Director of Glenmark Pharmaceuticals, believes that the clinical study approval of the novel molecule, which is a part of the newly established Innovative Medicines Group within the organization, will strengthen the company’s growth abilities of innovative clinical research and allow it to offer comprehensive cancer treatment solutions.

It is worth noting that Glenmark has a presence across generics, specialty, and OTC businesses. The company focuses on crucial therapeutic areas of oncology, dermatology, and respiratory. The company has nearly 10 manufacturing facilities across four continents and operates in more than 80 countries.

Source credits:

https://www.business-standard.com/article/pti-stories/glenmark-receives-dcgi-nod-to-conduct-clinical-trials-of-its-molecule-on-cancer-patients-122041100273_1.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Google Fi confirms data breach, leaking millions of customer’s data

Google Fi confirms data breach, leaking millions of customer’s data

By Akshay Kedari

Google Fi, Google's cell network operator, has reportedly revealed a data breach, which is most likely related to the T-recent Mobile's security disaster, which allowed hackers to leak millions of customers' personal information. The p...

European semiconductor giant ASML forecasts a sales surge for 2023

European semiconductor giant ASML forecasts a sales surge for 2023

By Akshay Kedari

Dutch semiconductor company ASML has reportedly forecast a revenue jump for the year 2023 as the global semiconductor industry anticipates a reacceleration of growth during the second half of this year. According to the firm, its net sales  f...

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

By Akshay Kedari

Following this funding, Interfor's long-term debt will hold a weighted average interest of 5.30% Interfor registered a Net Debt to the Invested Capital ratio of nearly 10% as of October 31, 2022 Interfor Corporation, one of the world...

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

By Akshay Kedari

Leading real estate services and investment company, ESR Group Limited, has recently announced that its exclusively-owned subsidiary, ARA and the Export-Import Bank of China have inked a breakthrough collaboration in a deal worth USD 1 billion infras...

Circularise nabs $11M to bring circular economy to industrial supply chains

Circularise nabs $11M to bring circular economy to industrial supply chains

By Akshay Kedari

Leading software platform, Circularise recently announced that it has raised $11.3 million (€11 million) in funding as part of its Series A round in a bid to advance its mission to bring a circular economy to industrial supply chains. The fun...